ArticleBMC public health2018
Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol.
Article in BMC public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03378765 (Gut Microbiota, Short Chain Fatty Acids, and Adiposity Across The Epidemiological Transition), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Gut Microbiota, Short Chain Fatty Acids, and Adiposity Across The Epidemiological Transition
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Gut Microbiota-microRNA Interactions and Obesity Pathophysiology: A Systematic Review of Integrated Studies.International journal of molecular sciences · 2024Pooled it
- Type 2 diabetes-associated gut microbial composition and short chain fatty acids differ across the epidemiologic transition in African origin populations.Gut microbes reports · 2027Article
- Eight-year prevalence and incidence of obesity, high blood glucose and high blood pressure in five African-origin populations: data from the Modeling the Epidemiologic Transition Study.BMJ public health · 2026Article
- Intestinal Microbiota in Early Life: Latest Findings Regarding the Role of Probiotics as a Treatment Approach for Dysbiosis.Nutrients · 2025Review
- Objectively measured moderate-to-vigorous physical activity does not attenuate prospective weight gain among african-origin adults spanning the epidemiological transition.Scientific reports · 2025Article
- Multiple low-dose radiation ameliorates type-2 diabetes mellitus via gut microbiota modulation to activate TLR4/MyD88/NF-κB pathway.BMC endocrine disorders · 2025Article
- Impact of Early-Life Microbiota on Immune System Development and Allergic Disorders.Biomedicines · 2025Review
- The role of microbiota in nonalcoholic fatty liver disease: mechanism of action and treatment strategy.Frontiers in microbiology · 2025Review
- Toxic metals impact gut microbiota and metabolic risk in five African-origin populations.Gut microbes reports · 2025Article
- The utility of physical activity questionnaires among African origin populations; lost in translation?Research square · 2024Article
- Sex-specific associations between self-reported sleep characteristics and 10-year cardiovascular disease risk in men and women of African descent living in a low socioeconomic status environment.Sleep epidemiology · 2024Article
- Metagenomic analysis of colonic tissue and stool microbiome in patients with colorectal cancer in a South Asian population.BMC cancer · 2024Article
- Article
- Associations between fears related to safety during sleep and self-reported sleep in men and women living in a low-socioeconomic status setting.Scientific reports · 2024Article
- Gut microbiome: New perspectives for type 2 diabetes prevention and treatment.World journal of clinical cases · 2023Review
- Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study.Nature communications · 2023Article
- Real‑world study of CervironBiomedical reports · 2023Article
- Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: The METS-Microbiome Study.Research square · 2023Article
- Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: The METS-Microbiome Study.bioRxiv : the preprint server for biology · 2023Article
- Obesity-Associated Neuropathy: Recent Preclinical Studies and Proposed Mechanisms.Antioxidants & redox signaling · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 6 countries.
Funding
Abstract
backgroundWhile some of the variance observed in adiposity and weight change within populations can be accounted for by traditional risk factors, a new factor, the gut microbiota, has recently been associated with obesity. However, the causal mechanisms through which the gut microbiota and its metabolites, short chain fatty acids (SCFAs) influence obesity are unknown, as are the individual obesogenic effects of the individual SCFAs (butyrate, acetate and propionate). This study, METS-Microbiome, proposes to examine the influence of novel risk factors, the gut microbiota and SCFAs, on obesity, adiposity and weight change in an international established cohort spanning the epidemiologic transition.
methodsThe parent study; Modeling the Epidemiologic Transition Study (METS) is a well-established and ongoing prospective cohort study designed to assess the association between body composition, physical activity, and relative weight, weight gain and cardiometabolic disease risk in five diverse population-based samples in 2500 people of African descent. The cohort has been prospectively followed since 2009. Annual measures of obesity risk factors, including body composition, objectively measured physical activity and dietary intake, components which vary across the spectrum of social and economic development. In our new study; METS-Microbiome, in addition to continuing yearly measures of obesity risk, we will also measure gut microbiota and stool SCFAs in all contactable participants, and follow participants for a further 3 years, thus providing one of the largest gut microbiota population-based studies to date. DISCUSSION: This new study capitalizes upon an existing, extensively well described cohort of adults of African-origin, with significant variability as a result of the widespread geographic distributions, and therefore variation in the environmental covariate exposures. The METS-Microbiome study will substantially advance the understanding of the role gut microbiota and SCFAs play in the development of obesity and provide novel obesity therapeutic targets targeting SCFAs producing features of the gut microbiota.
trial registrationRegistered NCT03378765 Date first posted: December 20, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.